TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9535211

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with peripheral blood progenitor cell transplantation (PBPCT) after two cycles of conventional chemotherapy (etoposide 500 mg/m2, ifosfamide 4 g/m2, cisplatin 50 mg/m2, epirubicin 50 mg/m2 plus granulocyte colony-stimulating factor 5 microg/kg) followed by high-dose etoposide 1,500 mg/m2, ifosfamide 12 g/m2, carboplatin 750 mg/m2, and epirubicin 150 mg/m2 with PBPCT.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Surgical resection in stages I to IIIA patients before high-dose chemotherapy.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy followed by high-dose chemotherapy and PBPCT.
Number of subjects: 16
Study: 7614524

Group type: EXPERIMENTAL
Intervention: Extended-release 5-ISMN 60 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extended-release 5-ISMN 120 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: ISDN 40 mg every 6 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24
Study: 2577308

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 406602

Group type: EXPERIMENTAL
Intervention: Verapamil, 80 mg three times/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Practolol, 100 mg three times/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30658629

Group type: EXPERIMENTAL
Intervention: Combined training: resistance + aerobic exercise program for nine months (n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 36
Study: 28844992

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 3770
Study: 26854054

Group type: EXPERIMENTAL
Intervention: Zero end‐expiratory pressure (ZEEP), n=25
Number of subjects: 50

Group type: COMPARATOR
Intervention: +5 PEEP, n=25
Number of subjects: 50
Study: 24033910

Group type: EXPERIMENTAL
Intervention: Intraventricular injection of low-dose rtPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (intraventricular injection of normal saline)
Number of subjects: 0
Study: 22726860

Group type: EXPERIMENTAL
Intervention: Coordinated inpatient rehabilitation system of care
Number of subjects: 26
Study: 20074703

Group type: EXPERIMENTAL
Intervention: Scopolamine (4.0 microg/kg IV)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17628683

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Ranibizumab (both dosages combined)
Number of subjects: 716

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 716
Study: 16125026

Group type: EXPERIMENTAL
Intervention: 10-contact, 20-week clinical nursing intervention
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conventional care control group
Number of subjects: 237
Study: 12543995

Group type: EXPERIMENTAL
Intervention: Supervised exercise and physiotherapy program (PTEX), n = 27, 12-week program, 3 times per week, 60 to 90 minutes per session, resistance and aerobic exercises at 70 to 85% of maximal effort
Number of subjects: 53

Group type: COMPARATOR
Intervention: Home-delivered physical and occupational therapy (PT), n = 26, no supervised exercise
Number of subjects: 53
Study: 10549211

Group type: EXPERIMENTAL
Intervention: Oro-mandibular dysfunction, anxiety, muscular stress
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study: 9117191

Group type: EXPERIMENTAL
Intervention: Trainees
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Instructors
Number of subjects: 85

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 85
Study: 1803995

Group type: EXPERIMENTAL
Intervention: Zidovudine 300 mg daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zidovudine 600 mg daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Zidovudine 300 mg daily plus acyclovir 4800 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Zidovudine 600 mg daily plus acyclovir 4800 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Zidovudine 1500 mg daily plus acyclovir 4800 mg daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High doses of zidovudine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zidovudine with high-dose acyclovir
Number of subjects: 41
Study: 6519349

Group type: EXPERIMENTAL
Intervention: Aspirin/Caffeine combination (800 mg aspirin, 65 mg caffeine)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Acetaminophen/Aspirin combination (648 mg acetaminophen, 648 mg aspirin)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 31292983

Group type: EXPERIMENTAL
Intervention: Immediate provisionalization (non-occluding temporary crown)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healing abutment (no provisionalization)
Number of subjects: 40
Study: 28141781

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 26498405

Group type: EXPERIMENTAL
Intervention: Qualitative methods in a randomized controlled trial (RCT) of a complex community intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed methods approach (qualitative and quantitative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research
Number of subjects: 0
Study: 23521532

Group type: COMPARATOR
Intervention: Standard evening meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Test evening meal enriched in protein (300 g of 0%‐fat fromage frais)
Number of subjects: 28
Study: 21159889

Group type: EXPERIMENTAL
Intervention: Pancolonic chromoendoscopy (PCC) with 0.4% indigo carmine spraying during continuous extubation
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Standard colonoscopy (control group)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1008
Study: 19460503

Group type: EXPERIMENTAL
Intervention: Tacrolimus and Mycophenolate Mofetil (TAC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Everolimus and low-dose Cyclosporine (EVL)
Number of subjects: 60
Study: 17509729

Group type: EXPERIMENTAL
Intervention: Educational program including performance feedback, clinician education, and patient educational materials.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control sites (no educational intervention).
Number of subjects: 16
Study: 15382101

Group type: EXPERIMENTAL
Intervention: Four-layer bandages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-stretch bandages
Number of subjects: 0
Study: 12488062

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9684948

Group type: EXPERIMENTAL
Intervention: Hypericum extract WS 5572 (5% hyperforin)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Hypericum extract WS 5573 (0.5% hyperforin)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 7988130

Group type: EXPERIMENTAL
Intervention: Bird VIP ventilator
Number of subjects: 9

Group type: COMPARATOR
Intervention: Siemens Servo 900C ventilator
Number of subjects: 9

Group type: COMPARATOR
Intervention: Newport Wave E200 ventilator
Number of subjects: 9
Study: 2679843

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 770329

Group type: EXPERIMENTAL
Intervention: Attenuated rubella virus vaccine (administered by nose drops or subcutaneous route)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nose drops and subcutaneous route groups
Number of subjects: 0
Study: 31891374

Group type: EXPERIMENTAL
Intervention: 4 cups of instant regular coffee (n = 62)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 4 cups of a coffee-like placebo beverage (n = 64)
Number of subjects: 126
Study: 31640806

Group type: EXPERIMENTAL
Intervention: Mental Health Continuum-Short Form (MHC-SF)
Number of subjects: 1175
Study: 28768651

Group type: EXPERIMENTAL
Intervention: RCE (60 mg isoflavone aglycones/d and probiotics)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (masked placebo)
Number of subjects: 78
Study: 26939312

Group type: EXPERIMENTAL
Intervention: Fixed Appliance (FA) with brackets and wires
Number of subjects: 64

Group type: COMPARATOR
Intervention: Removable Appliance (RA) comprising acrylic plates with protruding springs
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fixed Appliance (FA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Removable Appliance (RA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both Fixed and Removable Appliances
Number of subjects: 64
Study: 23983256

Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5FU/LV)
Number of subjects: 607

Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (5FU/LV) with irinotecan (IFL)
Number of subjects: 607
Study: 21914263

Group type: EXPERIMENTAL
Intervention: Vitrectomy without internal limiting membrane peeling (non-gas tamponade group)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vitrectomy without internal limiting membrane peeling but combined with gas tamponade (gas tamponade group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no surgical treatment)
Number of subjects: 49
Study: 19721215

Group type: EXPERIMENTAL
Intervention: Standard protocol (Std): 100‐Hz, 450‐micros pulses, amplitude set to evoke 75% of maximal voluntary isometric torque (MVIT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Short pulse duration protocol (SP): 100‐Hz, 150‐micros pulses, amplitude set to evoke 75% of MVIT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low-frequency protocol (LF): 25‐Hz, 450‐micros pulses, amplitude set to evoke 75% of MVIT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low-amplitude protocol (LA): 100‐Hz, 450‐micros pulses, amplitude set to evoke 45% of MVIT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Torque per active area (calculated from a companion study)
Number of subjects: 7
Study: 17597267

Group type: EXPERIMENTAL
Intervention: Plasmids encoding type 1 and type 2 E2 administered to mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRES-containing plasmids
Number of subjects: 0
Study: 15285276

Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 11411907

Group type: EXPERIMENTAL
Intervention: Uncommon TNF A II allele in patients with sarcoidosis-associated erythema nodosum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythema nodosum without underlying sarcoidosis
Number of subjects: 0
Study: 9753532

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 36
Study: 8119009

Group type: EXPERIMENTAL
Intervention: Tourniquet release for hemostasis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no tourniquet release)
Number of subjects: 100
Study: 1968000

Group type: EXPERIMENTAL
Intervention: Levonorgestrel and ethinyl oestradiol (0.15 mg levonorgestrel and 0.03 mg ethinyl oestradiol)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Desogestrel and ethinyl oestradiol (0.15 mg desogestrel and 0.03 mg ethinyl oestradiol)
Number of subjects: 84
Study: 880023

Group type: EXPERIMENTAL
Intervention: 14‐4 jejunoileostomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Modified gastric bypass (90% stomach bypassed)
Number of subjects: 200
Study: 31577451

Group type: EXPERIMENTAL
Intervention: Pioglitazone (a PPARÎ³ agonist)
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: PPARÎ³ agonists of the TZD-class
Number of subjects: 3876
Study: 28855352

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (50 mg twice a day for 2 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 55
Study: 26683252

Group type: EXPERIMENTAL
Intervention: Standard smoking cessation treatment plus exercise and counseling (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard smoking cessation treatment plus a time‐to‐contact control intervention on health education (n = 35)
Number of subjects: 70
Study: 24185462

Group type: EXPERIMENTAL
Intervention: Cortical tenting technique
Number of subjects: 6

Group type: COMPARATOR
Intervention: Onlay layered technique
Number of subjects: 6
Study: 22340231

Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 19787537

Group type: EXPERIMENTAL
Intervention: Performance-avoidance goals
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Mastery-avoidance goals
Number of subjects: 138

Group type: COMPARATOR
Intervention: All four goal conditions
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Personal achievement goals
Number of subjects: 138
Study: 18075046

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20
Study: 15564946

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.0 mg/ml, Fentanyl 1.4 microg/ml, Clonidine 0.5 microg/ml
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.9 mg/ml, Fentanyl 3.0 microg/ml, Clonidine 0.3 microg/ml
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.6 mg/ml, Fentanyl 2.5 microg/ml, Clonidine 0.8 microg/ml
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.0 mg/ml, Fentanyl 2.4 microg/ml, Clonidine 1.0 microg/ml
Number of subjects: 118
Study: 11949100

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional cuddling care (CCC)
Number of subjects: 30
Study: 8610863

Group type: EXPERIMENTAL
Intervention: Intraarticular ketorolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of intraarticular ketorolac and morphine
Number of subjects: 0
Study: 1551352

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4067783

Group type: EXPERIMENTAL
Intervention: Lactose (Group L)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sucrose (Group S)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 30956804

Group type: EXPERIMENTAL
Intervention: 30 min/day of in-bed cycling and routine physiotherapy (Cycling)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine physiotherapy alone (Routine)
Number of subjects: 66
Study: 29854081

Group type: EXPERIMENTAL
Intervention: Low frequency electroacupuncture (LEA)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High frequency electroacupuncture (HEA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham electroacupuncture (SEA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 5

Group type: COMPARATOR
Intervention: Diabetic group (DM)
Number of subjects: 5
Study: 26873052

Group type: EXPERIMENTAL
Intervention: Supplemental measles vaccine (sMV) administered at median age of 20 months after 1 or 2 doses of primary measles vaccination
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: Supplemental measles vaccine (sMV) administered at median age of 20 months after 2 doses of primary measles vaccination
Number of subjects: 1756
Study: 24853619

Group type: EXPERIMENTAL
Intervention: ExMI
Number of subjects: 158

Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 158

Group type: COMPARATOR
Intervention: COC
Number of subjects: 158
Study: 22442709

Group type: EXPERIMENTAL
Intervention: Cortisol response to anticipated interaction with dissimilar out-group member
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cortisol response to anticipated interaction with similar out-group member
Number of subjects: 0
Study: 19506136

Group type: EXPERIMENTAL
Intervention: Respiratory interventions (tracheostomy and noninvasive ventilation)
Number of subjects: 2477

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 2477

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 2477

Group type: COMPARATOR
Intervention: Death
Number of subjects: 2477
Study: 17327305

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (Wellbutrin XL) during acute phase (10 weeks)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (Wellbutrin XL) during maintenance phase (24 weeks)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (Wellbutrin XL)
Number of subjects: 93
Study: 15825029

Group type: EXPERIMENTAL
Intervention: gD vaccine with adjuvants (alum and MPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gD vaccine
Number of subjects: 0
Study: 11998240

Group type: EXPERIMENTAL
Intervention: Nurses' involvement in research
Number of subjects: 0
Study: 9523774

Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy (30 mW .83 microm GaAlAs continuous-wave infrared diode laser)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (dummy irradiation)
Number of subjects: 32
Study: 7664856

Group type: EXPERIMENTAL
Intervention: Cyclosporin therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 2696550

Group type: EXPERIMENTAL
Intervention: Felbinac gel applied three times daily
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 1011296

Group type: EXPERIMENTAL
Intervention: Aspartame (1.8 g administered three times daily with meals)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (administered three times daily with meals)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30777115

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) exercise with very low load (10% of 1-RM) and low volume
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-intensity resistance exercise (HIRE) (60% of 1-RM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) exercise with very low load and low volume
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-intensity resistance exercise (HIRE)
Number of subjects: 40
Study: 28240575

Group type: EXPERIMENTAL
Intervention: Dentists' perception of patient interest in sedation/general anesthesia (GA)
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Dentists' perception of patient interest in sedation/GA depending on cost
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Dentists' perception of patient fear levels
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Dentists' perception of patients avoiding dental care
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Comparison of dentist responses with patient responses from a 2002 national survey
Number of subjects: 1076
Study: 25958714

Group type: EXPERIMENTAL
Intervention: VIMA (8% sevoflurane)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TIVA (propofol to reach 8 mcg/ml)
Number of subjects: 100
Study: 23537976

Group type: EXPERIMENTAL
Intervention: Radial access catheterization
Number of subjects: 9126

Group type: COMPARATOR
Intervention: Delayed, provisional eptifibatide
Number of subjects: 9126
Study: 21110411

Group type: EXPERIMENTAL
Intervention: Energy restriction/training group (RE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Energy restriction group (R)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exercise training at maximum lipid-oxidation group (E)
Number of subjects: 28
Study: 20232014

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 16
Study: 16846663

Group type: EXPERIMENTAL
Intervention: SUCROSE: 9.9% sugar, 132 kcal
Number of subjects: 0

Group type: COMPARATOR
Intervention: CONTROL: 3% sucrose, 40 kcal
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASPARTAME: 3% sucrose 40 kcal plus artificial sweeteners ASPARTAME
Number of subjects: 0
Study: 15184611

Group type: EXPERIMENTAL
Intervention: Natalizumab 1 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Natalizumab 3 mg/kg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Natalizumab (both doses)
Number of subjects: 180
Study: 10906006

Group type: EXPERIMENTAL
Intervention: Ritanserin 2.5 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg/day
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 9065720

Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT) after preparatory regimen of fractionated total body irradiation (FTBI) 1,320 cGy and high-dose etoposide (VP-16) 60 mg/kg
Number of subjects: 33
Study: 8443034

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment once daily for 2 weeks
Number of subjects: 10
Study: 3537784

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 60
Study: 31148099

Group type: COMPARATOR
Intervention: Nimodipine 90 mg/die t.i.d plus placebo b.i.d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg t.i.d plus choline alphoscerate 1200 mg/die b.i.d
Number of subjects: 0